Metformin: historical overview

Diabetologia

Volumn 60, Issue 9, 2017, Pages 1566-1576

  Bailey, Clifford J ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

Biguanide; Dimethylbiguanide; Galega officinalis; Guanidine; History; Jean Sterne; Metformin; Review; Type 2 diabetes

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE;

EDITORIAL; GALEGA; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFLUENZA A; INSULIN RESISTANCE; LACTIC ACIDOSIS; LONG TERM CARE; MALARIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; UNITED STATES; WEIGHT GAIN;

BIGUANIDES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN;

EID: 85026812421     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-017-4318-z     Document Type: Editorial

References (92)

1. Bailey CJ, Day C (2004) Metformin: its botanical background. Pract Diabetes Int 21:115–117
2. Culpeper N (1995) Culpeper’s complete herbal: a book of natural remedies for ancient ills. Wordsworth Editions Ltd, Ware, Hertfordshire p335. Available from https://books.google.co.uk/books?id=aGih_JZtPvoC&pg=PA335&lpg=PA335&dq=galega+culpeper+herbal&source=bl&ots=77gExCABa_&sig=wV0BcjUm_RS8F6ZRMjo8N8F6zgU&hl=en&sa=X&ved=0ahUKEwiPw_fJ6YzSAhUBJcAKHV4EB2kQ6AEIQTAH#v=onepage&q=galega%20culpeper%20herbal&f=false. Accessed 13 Feb 2017
3. Hill J (1772). The vegetable system. Or the internal structure and the life of plants; their parts, and nourishment, explained; their classes, orders, genera, and species, ascertained, and described; in a methods altogether new: comprehending an artificial index, and a natural system. With figures of all the plants; designed and engraved by the author. The whole from nature only. Vol. XXI, containing plants and four-petal’d irregular flowers. London, p54
4. Hadden DR (2005) Goat’s rue—French lilac – Italian fitch – Spanish sainfoin: gallega officinalis and metformin: the Edinburgh connection. J R Coll Physicians Edinb 35:258–260
5. Galega officinalis. Available from https://en.wikipedia.org/wiki/Galega_officinalis. Accessed 27 Feb 2017
6. Pasik C (1997) Diabetes and the biguanides: the mystery of each. In: Pasik C (ed) Glucophage: serving diabetology for 40 years. Groupe Lipha, Lyon, p79
7. Watanabe CK (1918) Studies in the metabolic changes induced by administration of guanidine bases. Influence of injected guanidine hydrochloride upon blood sugar content. J Biol Chem 33:253–265
8. Frank E, Nothmann M, Wagner A (1926) Über synthetisch dargestellte Körper mit insulinartiger Wirkung auf den normalen und diabetischen Organismus. Klin Wchnschr 5:2100–2107 [article in German]
9. Simonnet H, Tanret G (1927). Sur les proprietes hypoglycemiantes du sulfate de galegine. Bull Soc Chim Biol Paris, 8 [article in French]
10. Bischoff F, Sahyun M, Long ML (1928) Guanidine structure and hypoglycemia. J Biol Chem 81:325–349
11. Muller H, Reinwein H (1927) Zur Pharmakologie des Galegins. Arch Exp Path Pharmacol 125:212–228 [article in German]
12. Rabinowiz IM (1927) Observations on the use of synthalin in the treatment of diabetes mellitus. Can Med Assoc J 17:901–904
13. Leclerc H. Le galega. Presse Med 1928, 22 décembre [article in French]
14. Howlett HCS, Bailey CJ (2007) Galegine and antidiabetic plants. In: Bailey CJ, Campbell IW, JCN C et al (eds) Metformin—the gold standard: a scientific handbook. Wiley, Chichester, pp 3–9
15. Parturier H, Hugnot G (1935). Le galega dans le traitement du diabète. Massons, Paris [article in French]
16. Rathke B (1879) Uber Biguanid. Ber Dtsch Chem Ges 12:776–784 [article in German]
17. Werner EA, Bell J (1922) The preparation of methylguanidine, and of ββ-dimethylguanidine by the interaction of dicyandiamide, and methylammonium and dimethylammonium chlorides respectively. J Chem Soc Trans 121:1790–1794
18. Hesse G, Taubmann G (1929) Die Wirkung des Biguanids und seiner Derivate auf den Zuckerstoffwechsel. Arch Exp Path Pharmacol 142:290–308 [article in German]
19. Slotta KH, Tschesche R (1929) Uber Biguanide. Die blutzuckersenkende Wirkung der Biguanides. Ber Dtsch Chem Ges 62:1398–1405 [article in German]
20. Curd FHS, Davey DG, Rose FL (1945) Studies on synthetic antimalarial drugs. Some biguanide derivatives as new types of antimalarial substances with both therapeutic and causal prophylactic activity. Ann Trop Med Parasitol 39:208–216
21. Chen KK, Anderson RC (1947) The toxicity and general pharmacology of N1-p-chlorophenyl-N5-isopropyl biguanide. J Pharmacol Exp Ther 91:157–160
22. Garcia EY (1950) Flumamine, a new synthetic analgesic and anti-flu drug. J Philippine Med Assoc 26:287–293
23. Pasik C (1997) Jean Sterne: a passion for research. In: Pasik C (ed) Glucophage: serving diabetology for 40 years. Lyon, Groupe Lipha, pp 29–31
24. Sterne J (1957) Du nouveau dans les antidiabétiques. La NN dimethylamine guanyl guanidine (N.N.D.G.) Maroc Med 36:1295–1296 [article in French]
25. Sterne J (1958) Blood sugar-lowering effect of 1,1-dimethylbiguanide. Therapie 13:650–659 article in French
26. Sterne J (1959) Treatment of diabetes mellitus with N,N-dimethylguanylguanidine (LA. 6023, glucophage). Therapie 14:625–630 [article in French]
27. Sterne J (1963) Report on 5-years’ experience with dimethylbiguanide (metformin, glucophage) in diabetic therapy. Wien Med Wochenschr 113:599–602 [article in German]
28. Sterne J, Hirsch C (1964) Experimental basis for combined treatment of diabetes with the biguanide-sulfonamide association. Diabete 12:171–175 [article in French]
29. Sterne J (1964) Mechanism of action of antidiabetic biguanides. Presse Med 72:17–19 [article in French]
30. Sterne J (1969) Pharmacology and mode of action of the hypoglycemic guanidine derivatives. In: Campbell GD (ed) Oral hypoglycemic agents. Academic Press, London, pp 193–245
31. Sterne J, Duval D, Junien JL (1979). Aspects of pharmacology and mechanisms of action. In: Cudwoth AG (ed) Metformin: current aspects and future developments. Research and Clinical Forums, Vol. 1, Tunbridge Wells, pp 13–20
32. Ungar G, Freedman L, Shapiro SL (1957) Pharmacological studies of a new oral hypoglycemic drug. Proc Soc Exp Biol Med 95:190–192
33. Beringer A (1958) Zur Behandlung der Zuckerkrankheiten mit Biguaniden. Wien Med Wschr 108:880–882 [article in German]
34. 1—3N1-alkyl- and aralkylbiguanides. J Am Chem Soc 81:3728–3736
35. Beckmann R (1971) Biguanide (Experimenteller Teil). Handb Exp Pharmacol 29:439–596 [article in German]
36. Azerad E, Lubetzki J (1959) Treatment of diabetes with N,N-dimethyl diguanide (LA6023). Presse Med 67:765–767 [article in French]
37. McKendry JB, Kuwayti K, Rado PP (1959) Clinical experience with DBI (phenformin) in the management of diabetes. Can Med Assoc J 80:773–778
38. Mehnert H, Seitz W (1958) Weitere Ergebnisse der Diabetesbehandlung mit blutzuckersenkenden Biguaniden. Münch Med Wochenschr 100:1849–1851 [article in German]
39. Butterfield WJ (1968) The effects of phenformin on peripheral glucose utilization and insulin action in obesity and diabetes mellitus. Ann N Y Acad Sci 148:724–733
40. Schäfer G (1983) Biguanides: a review of history, pharmacodynamics and therapy. Diabete Metab 9:148–163
41. Hermann LS (1979) Metformin: a review of its pharmacological properties and therapeutic use. Diabete Metab 5:233–245
42. Clarke BF, Duncan LJP (1968) Comparison of chlorpropamide and metformin treatment on weight and blood-glucose response of uncontrolled obese diabetics. Lancet 291:123–126
43. Clarke B, Campbell IW (1977) Comparison of metformin and chlorpropamide in non-obese maturity-onset diabetic uncontrolled on diet. Br Med J 275:1576–1578
44. Campbell IW, Howlett HC (1995) Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab Res Rev 11(Suppl 1):S57–S62
45. Bailey CJ (1992) Biguanides and NIDDM. Diabetes Care 15:755–772
46. Walker RS, Linton AL (1959) Phenethylbiguanide: a dangerous side effect. Br Med J 2:1005–1006
47. Luft D, Schmulling RM, Eggstein M (1978) Lactic acidosis in biguanide-treated diabetics. Diabetologia 14:75–87
48. University Group Diabetes Program (1975) A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Evaluation of phenformin therapy. Diabetes 24(Suppl 1):65–184
49. Nattrass M, Alberti KGMM (1978) Biguanides. Diabetologia 14:71–74
50. Bailey CJ, Nattrass M (1988) Treatment—metformin. Ballière’s Clin Endocrinol Metab 2:455–476
51. Lalau JD (2010) Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf 33:727–740
52. Shah RR, Oates NS, Idle JR, Smith RL (1980) Genetic impairment of phenformin metabolism. Lancet 315:1147
53. Bosisio E, Kienle MG, Galli G et al (1981) Defective hydroxylation of phenformin as a determinant of drug toxicity. Diabetes 30:644–649
54. DeFronzo RA (1988) The triumvirate: β-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 37:667–687
55. Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37:1595–1607
56. Howlett HCS, Bailey CJ (2007) Metformin: a chemical perspective. In: Bailey CJ, Campbell IW, Chan JCN et al (eds) Metformin, the gold standard. A scientific handbook. Wiley, Chichester, pp 23–28
57. Bailey CJ, Puah JA (1986) Effect of metformin on glucose metabolism in mouse soleus muscle. Diabete Metab 12:212–218
58. Wollen N, Bailey CJ (1988) Inhibition of hepatic gluconeogenesis by metformin: synergism with insulin. Biochem Pharmacol 37:4353–4358
59. Bailey CJ, Wilcock C, Day C (1992) Effect of metformin on glucose metabolism in the splanchnic bed. Br J Pharmacol 105:1009–1013
60. Wilcock C, Bailey CJ (1994) Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 24:49–57
61. Bailey CJ, Mynett KJ, Page T (1994) Importance of the intestine as a site of metformin-stimulated glucose utilization. Brit J Pharmacol 112:671–675
62. Wiernsperger NF, Bailey CJ (1999) The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs 58(Suppl 1):31–39
63. DeFronzo RA, Goodman AM, Multicenter Metformin Study Group (1995) Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541–549
64. Bailey CJ, Turner RC (1996) Drug therapy: metformin. N Engl J Med 334:574–579
65. Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ (2004) Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets—results of a retrospective cohort study. Curr Med Res Opin 20:565–572
66. Davidson J, Howlett H (2004) New prolonged-release metformin improves gastrointestinal tolerability. Br J Diabetes Vasc Dis 4:273–277
67. Garber AJ, Larsen J, Schneider SH, Piper BA, Henry D (2002) Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab 4:201–208
68. Bailey CJ, Day C (2009) Fixed-dose single tablet antidiabetic combinations. Diabetes Obes Metab 11:527–533
69. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865
70. Wiernsperger NF (2007) 50 years later: is metformin a vascular drug with antidiabetic properties? Br J Diabetes Vasc Dis 7:204–210
71. Bailey CJ (2008) Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drug Ther 22:215–224
72. Johnson JA, Simpson SH, Toth EL, Majumdar SR (2005) Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med 22:497–502
73. Eurich D, Majumdar SR, FA MA, Tsuyuki RT, Johnson JA (2005) Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28:2345–2351
74. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589
75. International Diabetes Federation Clinical Guidelines Task Force (2012). Global guideline for type 2 diabetes. Available from www.idf.org/e-library/guidelines/79-global-guideline-for-type-2-diabetes. Accessed 10 May 2017
76. Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of diabetes. Diabetologia 58:429–442
77. Garber AJ, Abrahamson MJ, Barzilay JI et al (2017) Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2017 executive summary. Endocr Pract 23:207–238
78. Qaseem A, Barry MJ, Humphrey LL, Forciea MA for the Clinical Guidelines Committee of the American College of Physicians (2017) Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 166:279–290
79. World Health Organization (2015). WHO model list of essential medicines. Available from www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1. Accessed 10 Feb 2017
80. Ferguson AW, De La Harpe PL, Farquhar JW (1961) Dimethyl biguanide in the treatment of diabetic children. Lancet 1:1367–1369
81. Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403
82. Hostalek U, Gwilt M, Hildemann S (2015) Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs 75:1071–1094
83. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP for the MiG Trial Investigators (2008) Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 358:2003–2015
84. Nestler JE (2008) Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 358:47–54
85. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S (2000) Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 284:472–477
86. Tankova T, Koev D, Dakovska L, Kirilov G (2002) Therapeutic approach in insulin resistance with acanthosis nigricans. Int J Clin Pract 56:578–581
87. Moreira PI (2014) Metformin in the diabetic brain: friend or foe? Ann Transl Med 2:54
88. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304–1305
89. Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766–1777
90. Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA (2016) Metformin as a tool to target aging. Cell Metab 23:1060–1065
91. McCreight LJ, Bailey CJ, Pearson ER (2016) Metformin and the gastrointestinal tract. Diabetologia 59:426–435
92. Scheen AJ (1996) Clinical pharmacokinetics of metformin. Clin Pharm 30:359–371